HKEX 02279 · Independent company profile

Yonghe Medical

Yonghe Medical Group Co., Ltd.

From one hair transplant to a full-cycle hair-care relationship.

Yonghe Medical provides hair-transplant services, medical hair care and related ancillary services.

Disclosure data through 2026-06-30 Page reviewed 2026-08-30 Listing Hong Kong Stock Exchange

Page two · play it → Investor relations ir@zhifa.cn Official company source

Latest disclosure sources: Financial data · HKEX PDF page 1; Institution network · HKEX PDF page 2; Consumer volume · HKEX PDF page 5. PureIR is an independent publisher and not Yonghe Medical’s official website.

A FIELD OF CARE 00

Press, then brush slowly across the field

01 Hair assessment
02 Hair transplant
03 Medical hair care
04 Ongoing relationship

An editorial metaphor for the disclosed service model; it does not represent an individual medical outcome.

63transplant institutions

40,793hair-transplant consumers

56,757medical hair-care consumers

Continue into the latest disclosure

Latest formal disclosure

Formal 2026 interim results

Formally released · unaudited Announcement published 20 August 2026

Interim revenue

RMB980.6m Up 13.8% year on year; hair-transplant service revenue rose 12.3% and medical hair-care service revenue rose 20.7%. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Interim net profit

RMB75.5m Up 170.9% from RMB27.9 million in the prior-year period; net margin was 7.7%. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Interim gross margin

69.0% Up 5.1 percentage points from 63.9% in the prior-year period; interim gross profit was RMB676.9 million. Six months ended 30 June 2026 · percent HKEX · PDF page 1

The figures below are from the formal interim-results announcement for the six months ended 30 June 2026. They are unaudited and compared with the prior-year period; five-year charts continue to use full fiscal years.

Disclosure highlights

Latest disclosure summary

Cover of Yonghe Medical 2025 annual report — 2025 annual report · published 16 April 2026 · 318 PDF pages

Company disclosure

65,708 consumers

Interim service scale

40,793 hair-transplant consumers, up 21.8%, and 56,757 medical hair-care consumers, up 26.4%; the two service counts may overlap.

Period: six months ended 30 June 2026; Currency/unit: consumers; HKEX PDF page 2; Hair-transplant consumers · PDF page 4; Medical hair-care consumers · PDF page 5

Company disclosure

63 transplant clinics

Hair-care network

Covering 61 cities nationwide, plus seven stand-alone Svenson stores; transplant-clinic count was unchanged from 2025 year-end.

Period: as at 30 June 2026; Currency/unit: institutions; HKEX PDF page 2

Company disclosure

RMB883.6m

Cash resources

Cash, cash equivalents and term deposits; interim net operating cash flow was RMB263.7 million and the Group had no bank borrowings.

Period: as at 30 June 2026; Currency/unit: RMB million; HKEX PDF page 18

Disclosure-led narrative

How to read the disclosure

Results, operating variables and calculated observations are shown together without crossing the disclosure boundary.

PureIR disclosure summary

Interim revenue and profit continued to improve

First-half 2026 revenue rose 13.8%, gross margin increased from 63.9% to 69.0%, and net profit rose 170.9% to RMB75.5 million. This describes disclosed results and is not a forecast.

HKEX PDF page 1

PureIR disclosure summary

Service volume supported both operating lines

In first-half 2026, hair-transplant consumers rose 21.8% while average spend declined 7.8%, supporting 12.3% segment revenue growth. Medical hair-care consumers rose 26.4% and related revenue grew 20.7%.

HKEX PDF page 5

PureIR calculated observation

Gross margin improved further with a stable network

The Group still operated 63 transplant clinics at 30 June 2026, unchanged from 2025 year-end, while interim gross margin rose 5.1 percentage points to 69.0%. Presenting the two together is a PureIR structured observation, not a causal claim.

HKEX PDF page 3；Additional source PDF page 1

Business model

Where revenue comes from

Medical service delivery is the core. Hair transplant contributes most revenue, while medical hair care supports an ongoing service relationship.

01Hair transplant 02Medical hair care 03Ongoing relationship

Hair transplant

RMB 1,375.1m

76.0%

Medical hair care

RMB 409.2m

22.6%

Other

RMB 24.0m

1.3%

Period: year ended 31 December 2025; currency: RMB; units: million and share. Amounts are company disclosures; shares are recalculated from disclosed amounts. HKEX 2025 annual report, PDF page 14

Five-year financials

Financial performance and profitability

All years are in RMB. Charts show amounts in millions; the public JSON retains RMB thousands.

Annual series

Revenue and gross profit

Period: years ended 31 December; unit：RMB million；type: company disclosure. HKEX annual report, PDF page 7

Annual series

Gross and net margin

Period: years ended 31 December; unit：percent；type: company disclosure. HKEX annual report, PDF page 7

Five-year financial summary · years ended / dates as at 31 December · currency RMB
Metric	2021	2022	2023	2024	2025
Revenue (RMB m)	2,168.6	1,412.8	1,777.3	1,804.5	1,808.3
Gross profit (RMB m)	1,580.0	872.6	997.2	1,084.2	1,194.2
Profit/(loss) for the year (RMB m)	120.2	-85.9	-546.7	-226.6	73.6
Gross margin	72.9%	61.8%	56.1%	60.1%	66.0%
Cash and cash equivalents (RMB m)	1,566.2	565.1	603.2	487.8	699.0

Type: company disclosure; the source applies to every number in the table. HKEX 2025 annual report, PDF page 7. The annual report states that the five-year summary does not form part of the audited consolidated financial statements.

Operating metrics

Institutions, doctors and patients

The 2025 disclosure uses “consumers” instead of “patients”, while the doctor measure changes from registered doctors to professional-team doctors. Cross-year comparisons require care.

Annual series

Patients or consumers served

Period: years ended 31 December; unit：people；type: company disclosure. HKEX annual report, PDF page 15

Annual operating indicators · years ended / dates as at 31 December
Year	Hair-transplant people	Hair-care people	Average transplant spend	Doctors	Transplant institutions	Source
2021	58,464 people	105,275 people	RMB 26,643 / person	259 people	54 institutions	Patients p.15/16 Doctors p.10 Institutions p.8
2022	39,254 people	63,257 people	RMB 26,251 / person	294 people	63 institutions	Patients p.17/18 Doctors p.10 Institutions p.14
2023	61,071 people	78,687 people	RMB 22,174 / person	350 people	75 institutions	Patients p.18/19 Doctors p.24 Institutions p.9
2024	59,655 people	77,222 people	RMB 22,306 / person	242 people	66 institutions	Patients p.14/15 Doctors p.9 Institutions p.11
2025	71,380 people	79,492 people	RMB 19,265 / person	221 people	63 institutions	Patients p.15/16 Doctors p.132 Institutions p.12

Type: company disclosure. Currency applies only to average spending, in RMB/person; people and institution counts use people and institutions. The 2021 average transplant spend excludes Hong Kong Nu/Hart revenue and uses Mainland China patient volume.

Leadership profile

Company disclosure summary

Senior management

The 2025 annual report lists five members of senior management. Select a name to read the corresponding disclosed responsibilities and experience.

01 / 05

Zhang Yu

Founder, Executive Director, Chairman and Chief Executive Officer

Zhang Yu founded the Group in July 2010 and has served as chief executive officer since then. He is responsible for overall strategy, business direction and day-to-day operations. He has more than 20 years of experience in hair-related healthcare, entered the hair-transplant industry in March 2005 and established the Yonghe brand in 2010.

Position and biography as disclosed in the 2025 annual report. HKEX 2025 annual report, PDF page 35

No official portraits for these executives were published in the reviewed annual report or governance page. Portrait spaces are intentionally left blank.

Official market reference

Market reference

Official HKEX link

PureIR does not currently display or provide market-price data for download. View the latest quote for 02279 on HKEX’s official securities quote page.

View 02279 quote on HKEX

This link leaves PureIR. Market data and applicable terms are provided and managed by HKEX.

Principal risks

Formally disclosed risks

Company disclosure summary

Historical growth may not indicate future performance

The company discloses that historical business growth, revenue and profitability may not reflect future performance, and that its ability to execute business strategies will affect its success.

HKEX 2025 annual report, PDF page 41

Company disclosure summary

Brand and consumer perception

The company discloses that damage to its brand, market reputation or consumer perception could materially and adversely affect operating results and prospects.

HKEX 2025 annual report, PDF page 41

Formal sources

Formal sources and public data

Company facts use HKEX annual reports and formal disclosures. Five annual reports support the historical series, while the formal 2026 interim results are presented separately from the annual charts.

2025 Annual Report 2026-04-16 · 318 PDF pages 2024 Annual Report 2025-04-29 · 306 PDF pages 2023 Annual Report 2024-04-29 · 302 PDF pages 2022 Annual Report 2023-04-25 · 274 PDF pages 2021 Annual Report 2022-04-27 · 250 PDF pages 2026H1 Interim results for the six months ended 30 June 2026 2026-08-20 · 34 PDF pages

Structured fact data：Financial and operating indicators, source pages and disclosure-led summaries used on this page — not the full text or sentence-level extraction of five annual reports. The download supports checking, field reuse and machine reading; source and data-type labels should be retained.

Download structured JSON →

PureIR is an independent, unofficial information platform and does not represent Yonghe Medical. This page is not investment advice and provides no rating, target price or undisclosed forecast.